Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN ASIF ABBAS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1316145253
CMS profile
241356
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$304,032.12

320 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 4 of 7; records 151–200 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN ASIF ABBAS

NPI 1316145253 · CMS profile ID 241356

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316145253?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316145253?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316145253?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 320 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1316145253?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

320 matching records · $304,032.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 320 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 320.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $181.9806/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446227 CMS
ABBVIE INC. $383.9806/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446229 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0006/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879363 CMS
ABBVIE INC. $1,500.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446221 CMS
Merck Sharp & Dohme LLC $21.1106/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944692385 CMS
ABBVIE INC. $539.9606/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446219 CMS
E.R. Squibb & Sons, L.L.C. $4.4206/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879537 CMS
E.R. Squibb & Sons, L.L.C. $37.2406/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879551 CMS
E.R. Squibb & Sons, L.L.C. $36.0006/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879559 CMS
E.R. Squibb & Sons, L.L.C. $74.0606/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879555 CMS
Celgene Corporation $300.0006/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879567 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879341 CMS
E.R. Squibb & Sons, L.L.C. $68.2506/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879359 CMS
E.R. Squibb & Sons, L.L.C. $208.2606/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879365 CMS
ABBVIE INC. $1,500.0006/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446217 CMS
Incyte Corporation $50.1606/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021419 CMS
Incyte Corporation $158.4606/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021423 CMS
Incyte Corporation $22.6506/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021429 CMS
Incyte Corporation $48.6506/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021435 CMS
Incyte Corporation $24.3206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021437 CMS
Incyte Corporation $48.6506/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021439 CMS
Incyte Corporation $16.2206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021441 CMS
Incyte Corporation $61.8406/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021443 CMS
Incyte Corporation $24.3206/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021451 CMS
Incyte Corporation $158.4606/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021453 CMS
Incyte Corporation $26.0906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021233 CMS
Incyte Corporation $26.0906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021235 CMS
Incyte Corporation $13.2706/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021427 CMS
Incyte Corporation $52.1706/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021431 CMS
Incyte Corporation $52.1706/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021433 CMS
Incyte Corporation $26.0906/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021449 CMS
Incyte Corporation $304.9606/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021413 CMS
Incyte Corporation $175.0006/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021415 CMS
Incyte Corporation $125.0006/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021417 CMS
Incyte Corporation $52.2906/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021425 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0006/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879547 CMS
E.R. Squibb & Sons, L.L.C. $988.0006/02/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879321 CMS
E.R. Squibb & Sons, L.L.C. $587.7806/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879335 CMS
E.R. Squibb & Sons, L.L.C. $102.4206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879343 CMS
E.R. Squibb & Sons, L.L.C. $8.7506/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879347 CMS
JAZZ PHARMACEUTICALS INC. $35.6005/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951397715 CMS
JAZZ PHARMACEUTICALS INC. $212.9605/31/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951397717 CMS
ABBVIE INC. $2,500.0005/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446215 CMS
E.R. Squibb & Sons, L.L.C. $5,510.0005/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879509 CMS
Incyte Corporation $4,850.0005/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943021395 CMS
Novartis Pharmaceuticals Corporation $13.4105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893482285 CMS
ABBVIE INC. $1,500.0005/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890446213 CMS
E.R. Squibb & Sons, L.L.C. $118.5005/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879549 CMS
E.R. Squibb & Sons, L.L.C. $957.3205/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879553 CMS
E.R. Squibb & Sons, L.L.C. $340.9305/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932879557 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140,923.18 188
PY2020 $96,913.05 98
PY2021 $165,597.46 163
PY2022 $304,032.12 320
PY2023 $234,631.39 259
PY2024 $191,036.81 192
PY2025 $176,174.14 212

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $252,434.17 50
PY2024 Recipient $896.11 1
PY2023 Recipient $3,343.24 1
PY2022 Recipient $2,995.47 1
PY2021 Recipient $495.09 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135173
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/24/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135214
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,800.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Modular Phase I II Open Label Multi Centre Study to Evaluate the Safety Tolerability Pharmacokinetics Immunogenicity and Preliminary Efficacy of AZD4512 Monotherapy or in Combination with Anticancer Agents in Participants with Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1185554787
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135189
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135220
Principal investigator 1 Stemline Therapeutics Inc. $1,250.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135231
Principal investigator 1 Stemline Therapeutics Inc. $1,250.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135160
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135165
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135168
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135177
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135179
Principal investigator 1 Stemline Therapeutics Inc. $14,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135184
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135193
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135197
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135202
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135205
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135210
Principal investigator 1 Stemline Therapeutics Inc. $5,800.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135217
Principal investigator 1 Stemline Therapeutics Inc. $750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135224
Principal investigator 1 Stemline Therapeutics Inc. $23,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135228
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135235
Principal investigator 1 Stemline Therapeutics Inc. $4,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135240
Principal investigator 1 GlaxoSmithKline, LLC. $2,505.60 11/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158938
Principal investigator 1 GlaxoSmithKline, LLC. $5,821.20 10/29/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154359
Principal investigator 1 GlaxoSmithKline, LLC. $2,505.60 10/16/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158969
Principal investigator 1 GlaxoSmithKline, LLC. $3,720.60 09/23/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154344
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 09/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158934
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 09/12/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158956
Principal investigator 1 GlaxoSmithKline, LLC. $6,766.20 08/21/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161198
Principal investigator 1 GlaxoSmithKline, LLC. $3,450.60 08/14/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158964
Principal investigator 1 GlaxoSmithKline, LLC. $6,901.20 08/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161189
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 07/31/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161201
Principal investigator 1 GlaxoSmithKline, LLC. $9,655.88 07/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158952
Principal investigator 1 Stemline Therapeutics Inc. $20.90 07/08/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135128
Principal investigator 1 GlaxoSmithKline, LLC. $6,340.28 07/04/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158942
Principal investigator 1 Stemline Therapeutics Inc. $46.60 06/26/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135108
Principal investigator 1 Stemline Therapeutics Inc. $237.62 06/26/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135116
Principal investigator 1 Stemline Therapeutics Inc. $85.99 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135099
Principal investigator 1 Stemline Therapeutics Inc. $4,200.00 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135103
Principal investigator 1 Stemline Therapeutics Inc. $10.60 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135112
Principal investigator 1 Stemline Therapeutics Inc. $165.00 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135120
Principal investigator 1 Stemline Therapeutics Inc. $175.82 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135123
Principal investigator 1 GlaxoSmithKline, LLC. $3,720.60 06/19/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158948
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 05/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154354
Principal investigator 1 GlaxoSmithKline, LLC. $6,901.20 05/08/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154349
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154339
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158960
Principal investigator 1 GlaxoSmithKline, LLC. $3,250.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161194
Principal investigator 1 GlaxoSmithKline, LLC. $28,250.00 04/01/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161209
Principal investigator 1 GlaxoSmithKline, LLC. $6,340.28 03/19/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161204